Novartis, Sandoz and UBS: Switzerland’s quality test begins

Key takeaways

• Novartis, Sandoz and UBS report during a busy Swiss earnings week from 28 April 2026.

• Investors will look beyond headline profits and focus on guidance, pricing power and cost control.

• The bigger question is whether defensive Swiss names can still justify premium expectations.

Switzerland does not usually do market drama. It prefers precision, clean trains and companies that do not shout unless absolutely required. But this week gives investors a useful test of several long-term themes at once: healthcare resilience, generic drug pricing, banking integration, the strength of premium tourism and construction demand.

Novartis reports first-quarter results on 28 April 2026. Sandoz and UBS follow on 29 April 2026. Amrize, the North American building materials group spun out of Holcim, reports after the US market close on 29 April, with its investor call on 30 April.

The medicine cabinet gets inspected

Novartis is the biggest story of the week. The company develops patented medicines, meaning drugs protected by intellectual property for a limited period. That protection matters because it allows high prices before cheaper competition arrives.

The market will focus on whether Novartis can keep growing through its newer medicines while older blockbusters face patent pressure. Entresto, its heart drug, remains a key concern because generic competition can reduce sales quickly once protection fades. That is the basic pharmaceutical treadmill: yesterday’s miracle drug can become tomorrow’s discount aisle.

For long-term investors, the key issue is not one quarter of sales. It is whether the pipeline, meaning the future drug portfolio, can offset that patent loss. Watch management comments on cancer medicines, immunology, radiopharmaceuticals and guidance for the rest of 2026. A stable outlook would support the idea that Novartis remains a high-quality defensive compounder. A cautious outlook would remind investors that even defensive companies have expiry dates, sometimes literally.

Sandoz sits on the other side of that same story. It sells generics and biosimilars. Generics are cheaper copies of traditional drugs. Biosimilars are near-copies of complex biologic medicines. As healthcare systems try to cut costs, companies like Sandoz can benefit from demand for lower-cost treatments.

The question is whether Sandoz can turn demand into profitable growth. Investors will look at biosimilar momentum, price pressure and margins. The company has guided for faster growth in 2026, but generics remain a tough business. Volume can be strong, while prices behave like a polite guest who leaves early.

UBS: still integrating, still explaining

UBS is the other major event. The bank is still digesting Credit Suisse, which it acquired during the 2023 banking crisis. That deal made UBS larger and more important, but also more watched by regulators. For investors, the first-quarter update will be about three things: client money flows, cost savings and capital rules.

Client money flows show whether wealthy clients are still bringing assets to the bank. Cost savings show whether the Credit Suisse integration is becoming a profit engine rather than a large administrative sandwich. Capital rules show how much money UBS may need to hold back instead of returning to shareholders.

The Swiss government has proposed tougher rules for systemically important banks, especially around foreign subsidiaries. That may not hurt the business model overnight, but it could weigh on buybacks, dividends and valuation if investors believe UBS needs to carry more capital for longer.

Smaller signals from cement and mountains

Amrize makes building materials, mainly cement, aggregates, ready-mix concrete and related products used in roads, bridges, commercial buildings and housing. That makes it a clean read on North American construction demand. The focus will be pricing, volumes, infrastructure spending and housing repair activity. For a newly listed spin-off from Holcim, the market often wants simple proof: can the business stand alone, communicate clearly and keep margins steady?

Jungfraubahn operates the railway and mountain tourism infrastructure around the Jungfrau region in Switzerland, including routes that bring visitors to major Alpine attractions. That makes it less about earnings this week and more about tourism strength. The company reported a strong 2025, helped by high visitor numbers and higher revenue per guest. It is a useful reminder that premium travel can be surprisingly resilient, until weather, currencies or geopolitics decide to join the meeting.

Risks worth watching

The main risk for Novartis is that newer drugs do not grow fast enough to offset patent losses. For Sandoz, the risk is price pressure in generics or slower biosimilar adoption. For UBS, the risk is that integration costs, regulation or weaker client activity reduce the appeal of the post-Credit Suisse story.

Early warning signs include softer 2026 guidance, weaker margins, lower client inflows at UBS, or cautious comments on pricing. None of these would settle the long-term case in one quarter. But they would change the tone.

Investor playbook

• Watch guidance more than last quarter’s profit. The market usually pays for the future.
• Compare revenue growth with margin trends. Growth without profit discipline can be expensive exercise.
• For UBS, track client inflows and capital comments together. Both shape shareholder returns.
• Treat defensive stocks as businesses, not shelters. Quality still needs evidence.

Conclusion

This Swiss earnings week is not about fireworks. It is about pressure gauges. Novartis must show its next generation of medicines can carry the story forward. Sandoz must prove lower-cost healthcare can also mean better profitability. UBS must show that the Credit Suisse integration is becoming simpler, not just larger. Amrize and Jungfraubahn add useful side notes on construction and premium travel. Together, they offer a calm but important market lesson: “defensive” does not mean automatic. Even Switzerland’s steadiest companies still need to earn investor trust, one quiet quarter at a time.

This material is marketing content and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.

The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.